JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC

Clinical trial NCT06731153 · NOT_YET_RECRUITING

Trial details

NCT number: NCT06731153
Sponsor: Fudan University
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Triple Negative Breast Cancer (TNBC)Metastatic Breast Cancer

Start date: 2024-12-01
Primary completion: 2027-06-01
Enrollment: 40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.